560.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$547.18
Aprire:
$553.6
Volume 24 ore:
709.09K
Relative Volume:
1.17
Capitalizzazione di mercato:
$44.15B
Reddito:
$4.45B
Utile/perdita netta:
$1.10B
Rapporto P/E:
41.23
EPS:
13.591
Flusso di cassa netto:
$1.06B
1 W Prestazione:
+8.18%
1M Prestazione:
+9.10%
6M Prestazione:
-1.68%
1 anno Prestazione:
-12.08%
Idexx Laboratories Inc Stock (IDXX) Company Profile
Nome
Idexx Laboratories Inc
Settore
Industria
Telefono
(207) 556-0300
Indirizzo
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
560.36 | 44.15B | 4.45B | 1.10B | 1.06B | 13.59 |
|
TMO
Thermo Fisher Scientific Inc
|
690.00 | 255.13B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
229.04 | 161.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
393.44 | 56.71B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
172.97 | 48.77B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2026-04-15 | Iniziato | Citigroup | Neutral |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-31 | Aggiornamento | Stifel | Hold → Buy |
| 2025-10-01 | Iniziato | UBS | Neutral |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-01 | Iniziato | Jefferies | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | BTIG Research | Buy |
| 2024-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-12-04 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Downgrade | Stifel | Buy → Hold |
| 2022-07-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-07-12 | Iniziato | Piper Sandler | Overweight |
| 2022-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-08 | Iniziato | Atlantic Equities | Overweight |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-17 | Iniziato | Barclays | Overweight |
| 2019-09-09 | Iniziato | Goldman | Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Buy |
| 2018-11-02 | Reiterato | BofA/Merrill | Buy |
| 2018-05-07 | Reiterato | Stifel | Buy |
| 2018-01-16 | Iniziato | Piper Jaffray | Overweight |
| 2017-08-23 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Aggiornamento | CL King | Neutral → Buy |
| 2017-02-03 | Downgrade | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Ripresa | BofA/Merrill | Neutral |
| 2016-08-16 | Reiterato | Stifel | Buy |
| 2016-08-03 | Aggiornamento | Northcoast | Sell → Neutral |
| 2016-07-20 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-19 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-01 | Iniziato | CL King | Neutral |
| 2016-03-21 | Reiterato | Stifel | Buy |
| 2016-02-04 | Iniziato | Credit Suisse | Outperform |
| 2015-10-29 | Reiterato | Stifel | Buy |
| 2015-08-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Reiterato | Stifel | Buy |
| 2015-07-23 | Reiterato | Canaccord Genuity | Buy |
Mostra tutto
Idexx Laboratories Inc Borsa (IDXX) Ultime notizie
IDEXX Laboratories Inc (IDXX) Shares Surge 3.4% -- What GF Score of 96 Tells Investors - GuruFocus
IDEXX Laboratories stock sits 36.51 percent below USD 747.00 target - ad-hoc-news.de
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories’ Q3 2026 Earnings: What to Expect - Barchart.com
IDEXX Laboratories’ Q3 2026 Earnings: What to Expect - inkl
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
KeyBanc Initiates IDEXX Laboratories at Sector Weight - marketscreener.com
KeyBanc initiates Idexx Laboratories stock rating at Sector Weight - Investing.com
IDEXX Laboratories (IDXX) Stock Forecast and Price Target 2026 - MarketBeat
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
What IDEXX Laboratories Investors Missed Before The Fall - Simply Wall Street
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts keep Moderate Buy on IDEXX Laboratories stock - AD HOC NEWS
IDEXX Laboratories stock after-hours at EUR 469.60: plus 1.94 percent versus prior close - AD HOC NEWS
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX sets November 2 results date and IDEXX Laboratories stock costs EUR 462.25 - AD HOC NEWS
IDEXX Laboratories, Inc. Revenue Breakdown – XETR:IX1 - TradingView
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
IDEXX Laboratories to Release 2026 Third Quarter Financial Results - Business Wire
IDEXX CEO Jon Ayers stepping down after 17 years with company - DVM 360
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI - Yahoo Finance
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories - PR Newswire
An AI tool that helps veterinarians document care is now owned by IDEXX. - Stock Titan
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
IDEXX Laboratories stock falls 1.65 percent below USD 747 target - AD HOC NEWS
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories stock heads into the open after September 24 update - AD HOC NEWS
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Singapore
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History - Yahoo! Finance Canada
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Australia
Should You Continue to Hold IDXX Stock in Your Portfolio? - TradingView
IDEXX Laboratories Acquires CoVetAI to Enhance Veterinary Software Ecosystem - Global Legal Chronicle
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories stock gains 1.16 percent as valuation holds - AD HOC NEWS
IDEXX Laboratories stock heads into the open after recent gains - AD HOC NEWS
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof - DVM360
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets - Yahoo Finance
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference - Yahoo Finance
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics - Yahoo Finance
Idexx Laboratories Inc Azioni (IDXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Idexx Laboratories Inc Azioni (IDXX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LAWRENCE D KINGSLEY | Director |
Sep 04 '26 |
Proposed Sale |
532.08 |
2,203 |
1,172,178 |
0 |
| Kingsley Lawrence D | Director |
Sep 04 '26 |
Sale |
532.08 |
2,203 |
1,172,178 |
9,568 |
| Emerson Andrew | EVP, CFO and Treasurer |
Aug 20 '26 |
Option Exercise |
178.26 |
265 |
47,239 |
4,507 |
| FENNELL GEORGE | Executive Vice President |
Jun 01 '26 |
Option Exercise |
0.00 |
639 |
0 |
10,717 |
| Margaret Anne Szostak | Director |
May 20 '26 |
Proposed Sale |
553.58 |
1,344 |
744,012 |
0 |
| Kingsley Lawrence D | Director |
May 07 '26 |
Option Exercise |
0.00 |
339 |
0 |
9,568 |
| Peacock Karen | Director |
May 07 '26 |
Option Exercise |
0.00 |
101 |
0 |
102 |
| HOOLEY JOSEPH L | Director |
May 07 '26 |
Option Exercise |
0.00 |
158 |
0 |
276 |
| Vandebroek Sophie V. | Director |
May 07 '26 |
Option Exercise |
0.00 |
257 |
0 |
905 |
| JUNIUS DANIEL M | Director |
May 07 '26 |
Option Exercise |
0.00 |
257 |
0 |
3,561 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):